News

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human

Mainz, September 2017 – Am 14. September kommt im Rahmen der Seminarreihe in Translational Oncology (SITO) Prof. Federico Garrido der Universität von Granada Medical School nach Mainz. Sie sind herzlich zu seinem Vortrag um 17.00 Uhr c.t. in Gebäude 708 der Universitätsmedizin Mainz eingeladen.

Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach

Mainz, September 2017 – TRON will also participate at the THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE in Mainz this year. Meet and talk to our experts in: Bioinformatics: Wednesday, 12:30-2:00 pm Next Generation Sequencing: Wednesday, 3:00-4:00 pm Biomarker: Thursday, 11:30-1:00 pm Immunomonitoring: Thursday, 3:00-4:00 pm Pre-Clinical Research: Friday, 12:30-2:00 pm T-cell Vaccines & Immunotherapy: Friday,

Mainz, August 2017 – On Aug. 24th Dr. Evan Newell from the Singapore Immunology Network (SIgN) in Singapore is visiting Mainz in the context of the Seminars in Translational Oncology (SITO).

Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.

Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their

Mainz, June 2017 – On June 10, TRON participated in the charity event „Run for Children®“.

Mainz, June 2017 – Lena Kranz, PhD, has been awarded for her doctoral thesis the 2017 NMFZ prize of the Natural Science and Medical Research Center Mainz (NMFZ), part of the University Medical Center of Mainz.

Mainz, May 2017 – On May 10, 2017, Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in cancer immunotherapy research.

Mainz, April – Mustafa Diken, PhD, presented on this year’s AACR conference 2017 our recent work on nanoparticles and RNA vaccine for cancer therapy.

Mainz, April – The 32nd Annual Meeting of the Rheumatology Working Group (ARRP) and the cooperative Rheumazentrum Rheinland-Pfalz e.V. …

Mainz, March 2017 – On March 14, 2017 the 7th Ci3-Cluster conference took place in Mainz. The conference looked back at the successes resulting from the past five years of funding for projects in the Cluster for Individualized ImmunIntervention (Ci3) via the German Ministry for Education and Research (BMBF).

Mainz, March 2017 – The Research Institute for Translational Oncology (TRON) and the German Cancer Research Center (DKFZ) in Heidelberg join forces in a newly founded Helmholtz Institute for Translational Oncology (HI-TRON) at the University Medical Center Mainz.

Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the

Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine

Mainz, November 17 – ‘The immune biology of microsatellite instability cancer: Towards a vaccine against HNPCC’, Prof. von Knebel Doeberitz from the Institute of Pathology at the University of Heidelberg will speak in our seminar on Thursday during his visit at TRON.

Mainz, November 10 – ‘Inducing Neoantigens in Therapeutic and Prophylactic Cancer Immunotherapy’, Prof. Eli Gilboa from the Sylvester Comprehensive Cancer Center at the University of Miami will speak in our seminar on Thursday during his visit at TRON.

Mainz, September 29 – ‘Diabetes, beta-cells and reprogramming with mRNA: potential cell-based therapy for diabetes’ Tomáš Koblas of the Institute for Clinical and Experimental Medicine, Prague, will talk at Seminars in Translational Oncology (SITO) during his visit at TRON.

Milwaukee, WI, July 23, 2016 – ‘A message for immunity: Systemic nanoparticle RNA vaccines mimic infection to fight cancer’, The American Society of Gene & Cell Therapy (ASGCT) publishes an author summary of our publication by Lena M. Kranz and colleagues in the renowned scientific journal Nature.

Winchester, UK, September 13th – ” Systemic nanoparticle RNA vaccines mimic infection to fight cancer”, Lena M. Kranz will speak at the 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16), Session 5.

Vienna, September 01 2016 – TRON Scientific Manager Ugur Sahin will speak at the World Congress on Cancers of the Skin 2016. His talks will cover “Mutanome specific personalized vaccination” (11:30 a.m., 2016-09-01) and “RNA based mutanome specific vaccines – a true personalized therapy” (6:00 p.m., 2016-09-01).

Mainz, July 15 2016 – “Uptake of synthetic naked RNA by DCs allows antigen expression and induction of T-cell responses in mice” – TRON scientist shed further insight into the underlying mechanism of RNA uptake, translation and antigen presentation upon intradermal administration of antigen-encoding RNA.

Mainz, Juli 15 2016 – „Forschungsergebnisse werden zu Therapieverfahren”, Interview mit TRONs wisschenschaftlichem Direktor Prof. Dr. Ugur Sahin im SWR.

Mainz, June 30 2016 – “Tissue-resident regulatory T cells”, Dr. Markus Feuerer from the Helmholtz Young Investigator research group “Immune Tolerance” at the German Cancer Research Center (DKFZ), Heidelberg, Germany is visiting TRON. 5 PM, Lecture Hall Building 205, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany

Mainz, June 02 2016 Breaking News Publication in the renowned Nature journal describes first example of RNA-Lipoplexes as a novel vaccine class that exploit antiviral immune mechanisms for potent cancer immunotherapy. Read more about the media coverage for TRON’s most recent Nature publication here.

Mainz, June 09 2016 – “Abrogation of the immunosuppressive tumor-microenvironment in Hepatocellular Carcinoma by targeting Treg and co-inhibitory pathways”, Dr. Jaap Kwekkeboom & Dr. Dave Sprengers from Erasmus MC-University Medical Centre, Rotterdam are visiting TRON. 5 PM, Lecture Hall Building 708, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz

Mainz, April 28 2016 – “Exploiting Natural Killer cells for immunotherapy of cancer”, PD Dr. rer. nat. Adelheid Cerwenka from the German Cancer Research Center (DKFZ) is visiting TRON.

Mainz, April 7 2016 – “Regulation of tumor immunity by macrophage and eosinophils”, Prof. Günter Hämmerling from the German Cancer Research Center (DKFZ) is visiting TRON.

Davos, März 16, 2016 – “Eliciting potent T-cells against individual mutant neoantigens – the mutanome as rich target source for individualized cancer vaccination” Vortrag von Dr. Sebastian Kreiter in der Session “Immune Tolerance” auf dem 10. World Immune Regulation Meeting Davos (CH).